IDH1/2 mutations are druggable targets and are already exploited for therapeutic purposes in gliomas, cholangiocarcinoma, and acute myeloid leukemia (AML) [28,35], but, as we will see later, their significance as targets in CS clinical management is still under evaluation. This evidence concerns the gene IDH1 and central nervous system cancer.